Enhanced Sensitivity of Tumor Cells to Autophagy Inhibitors Using Fasting-Mimicking Diet and Targeted Lysosomal Delivery Nanoplatform
Source abstract
Abstract
Autophagy is one of the key pathways for tumor cell survival and proliferation. Therefore, inhibition of autophagy has been extensively studied for cancer therapy. However, current autophagy inhibitors lack specificity and are ineffective in limiting tumor progression. Herein, we report a nanoplatform for tumor-site-targeted delivery of hydroxychloroquine (HCQ) using insulin-like growth factors 2 receptor (IGF2R)-targeted liposomes (iLipo-H). A fasting-mimicking diet (FMD) is used to increase the autophagy levels in tumor cells, thereby increasing the sensitivity of tumor cells to HCQ. In addition, FMD treatment upregulates the expression of IGF2R in tumor cells, but not normal cells. Consequently, iLipo-H nanoparticles efficiently accumulate at the tumor site under FMD condition. In vivo studies demonstrate that iLipo-H nanoparticles efficiently inhibit 4T1 tumor growth without obvious side effects, especially under FMD condition. This study provides a promising strategy to increase the sensitivity of tumor cells to autophagy inhibitors for effective cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Autophagy in Disease and Therapy · Histone Deacetylase Inhibitors Research · Sirtuins and Resveratrol in Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150040, China
Funding
National Key R&D Program of China · The Strategic Priority Research Program of Chinese Academy of Sciences · Foundation of National Center for Nanoscience and Technology
References (32)
Show source-provided references
1. 10.1038/ncb0910-81410.1038/ncb0910-814 ↗
2. 10.4161/23723556.2014.98591310.4161/23723556.2014.985913 ↗
3. 10.1038/s41574-021-00551-910.1038/s41574-021-00551-9 ↗
4. 10.1038/nrc326210.1038/nrc3262 ↗
5. 10.1038/s41568-018-0030-710.1038/s41568-018-0030-7 ↗
6. 10.1016/j.molcel.2020.05.03410.1016/j.molcel.2020.05.034 ↗
7. 10.1038/s41467-020-17882-210.1038/s41467-020-17882-2 ↗
8. 10.1007/s00018-015-2104-y10.1007/s00018-015-2104-y ↗
9. 10.1016/j.phrs.2016.01.02810.1016/j.phrs.2016.01.028 ↗
10. 10.1038/s41580-019-0120-810.1038/s41580-019-0120-8 ↗
11. 10.1021/acs.biomac.7b0002310.1021/acs.biomac.7b00023 ↗
12. 10.1101/gad.159920710.1101/gad.1599207 ↗
13. 10.1073/pnas.070810010510.1073/pnas.0708100105 ↗
14. 10.1021/acs.nanolett.2c0035610.1021/acs.nanolett.2c00356 ↗
15. 10.1002/advs.20220048210.1002/advs.202200482 ↗
16. 10.1016/j.clnu.2017.06.01710.1016/j.clnu.2017.06.017 ↗
17. 10.1038/s41568-018-0048-x10.1038/s41568-018-0048-x ↗
18. 10.1021/acs.molpharmaceut.5b0017710.1021/acs.molpharmaceut.5b00177 ↗
19. 10.4161/auto.2348510.4161/auto.23485 ↗
20. 10.1002/advs.20190284710.1002/advs.201902847 ↗
21. 10.1021/nl501839q10.1021/nl501839q ↗
22. 10.1038/s41556-018-0201-510.1038/s41556-018-0201-5 ↗
23. 10.1074/jbc.M70282420010.1074/jbc.M702824200 ↗
24. 10.1080/15548627.2016.116293010.1080/15548627.2016.1162930 ↗
25. 10.1128/MCB.25.3.1025-1040.200510.1128/MCB.25.3.1025-1040.2005 ↗
26. 10.1021/acs.nanolett.9b0396810.1021/acs.nanolett.9b03968 ↗
27. 10.1002/advs.20200292210.1002/advs.202002922 ↗
28. 10.1016/j.jmb.2019.10.02810.1016/j.jmb.2019.10.028 ↗
29. 10.1080/15548627.2016.119275110.1080/15548627.2016.1192751 ↗
30. 10.1016/j.drup.2012.01.00410.1016/j.drup.2012.01.004 ↗
31. 10.1038/s41586-020-2229-510.1038/s41586-020-2229-5 ↗
32. 10.1021/acs.nanolett.2c0047810.1021/acs.nanolett.2c00478 ↗